Exact Sciences up 6% after hours on raised 2023 revenue guidance

Exact Sciences (NASDAQ:EXAS) is up ~6% in after-hours trading after boosting its 2023 revenue guidance, as well as posting Q1 results that beat on the top and bottom lines.
The company now projects 2023 revenue of $2.38B-$2.42B ($2.3B consensus). Previous guidance was $2.265B-$2.315B.
In the quarter, Exact Sciences (EXAS) saw its net loss narrow 59% to $74.2M (-$0.42 per share basic and diluted vs. -$1.04).
Total operating expenses in the quarter increased ~2% compared to the prior-year period to ~$679.5M.
Exact Sciences ended the quarter with cash and cash equivalents of $421.4M, a ~74% increase from Dec. 31, 2022.

More on Exact Sciences